According to FutureWise analysis the market for Critical Care Antiarrhythmic Drugs in 2023 is US$ 1 billion, and is expected to reach US$ 1.57 billion by 2031 at a CAGR of 5.82%.
Antiarrhythmic drugs used in critical care are medications that treat arrhythmias caused by serious cardiovascular conditions. In order to maintain the sinus beat, they monitor the heart's electrical conduction system. A number of medications are used to treat cardiac problems, including calcium channel blockers, antiadrenergic agents, antiarrhythmics, diuretics, and angiotensin-converting enzyme inhibitors. Antiarrhythmic medications prevent abnormal heart rhythms caused by atrial flutter, atrial and ventricular fibrillation, and other irregular heartbeats. Globally, cardiovascular diseases are on the rise, which is expected to propel the market's growth. Arrhythmias are irregular heartbeats caused by cardiovascular disorders such as atrial fibrillation (AFib). The rise in the incidence of disorders worldwide will, therefore, facilitate the expansion of the market. There are many arrhythmias that are treated in clinical practices, but AFib is the most common one. A major growth factor for the market has been the adoption of therapeutics for treating acute arrhythmia patients in intensive care units. Atrioventricular fibrillation is commonly observed in medical intensive care units (MICU), with almost 30% of patients observing atrial fibrillation during their stay. In ICUs, cardiac arrhythmias are common complications, with a high reported incidence of 40%.
A common problem observed in severely ill patients, including pulmonary and cardiac diseases, is the potential development of arrhythmias, making management and recognition in the ICU vital. In the forecast period, this is anticipated to be one of the key factors contributing to market growth. Growth of the market might be hindered by adverse effects caused by antiarrhythmic drugs. A number of class I antiarrhythmic drugs are used for treating different types of ventricular and atrial arrhythmias, including mexiletine, flecainide, propafenone, quinidine, and procainamide. There are some side effects associated with the antiarrhythmic drugs, such as central nervous system toxicity, cardiovascular toxicity, gastrointestinal symptoms, and immune-mediated reactions. In addition, cardiovascular diseases are expected to increase in both developed and developing countries in the forecast period, fueling demand for antiarrhythmic drugs. Increasing focus on heart health is driving the demand for critical care antiarrhythmic drugs, thereby driving market growth. Research and development (R D) activities in drug discovery are expected to boost market growth in the coming years.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Critical Care Antiarrhythmic Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Critical Care Antiarrhythmic Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.